METiS TechBio Licenses AI-Designed Trispecific T-Cell Engager MTS-128 to Boulevard Bio in Deal Worth Up to $1.6 Billion
核心洞察
METiS TechBio (搜索) has granted Boulevard Bio (搜索) exclusive global rights to develop, manufacture, and commercialize MTS-128 (搜索), an AI-designed trispecific T-cell engager.
The deal includes a $20 million upfront payment, up to $1.6 billion in milestone payments, and tiered royalties on product sales.
MTS-128 (搜索) was developed end-to-end through METiS's proprietary NanoForge AI platform, specifically its AiProtein engine for protein and antibody design.
METiS TechBio (搜索) (7666.HK), a Hong Kong-based AI-driven drug delivery company, announced on June 30, 2026, that it has entered into an exclusive global licensing agreement with Boulevard Bio (搜索), a U.S. biotechnology company backed by Deerfield Management (搜索). Under the terms of the agreement, Boulevard Bio receives worldwide development, manufacturing, and commercialization rights for MTS-128 (搜索), a proprietary trispecific T-cell engager (TCE) program developed entirely through METiS TechBio's NanoForge platform.
The financial terms are substantial: METiS TechBio (搜索) will receive a $20 million upfront payment and is eligible to receive up to $1.6 billion in development, regulatory, and commercial milestone payments, in addition to tiered royalties on product sales.
A New Class of T-Cell Engagers
MTS-128 (搜索) represents a next-generation approach to T-cell engager therapy. Unlike conventional bispecific T-cell engagers, trispecific TCEs can simultaneously engage multiple biological mechanisms. According to METiS TechBio (搜索), this multi-target engagement has the potential to enhance target cell killing efficiency, increase the therapeutic window, and reduce off-target toxicity.
The program was designed and optimized end-to-end through NanoForge-enabled AI-driven molecular engineering, distinguishing it from traditional antibody discovery approaches. The development of MTS-128 (搜索) reflects what the company describes as its integrated capabilities in artificial intelligence and protein engineering.
The NanoForge Platform
At the core of this transaction is METiS TechBio (搜索)'s proprietary NanoForge platform, built on an integrated "dry lab + wet lab + agent-based intelligence" innovation framework. The platform powers four core solution engines: AiLNP for AI-driven lipid nanoparticle design, AiRNA for AI mRNA sequence design, AiProtein for AI protein and antibody design, and AiTEM for AI small molecule formulation design.
The AiProtein platform, in particular, supports rapid discovery and optimization of novel therapeutic proteins, including T-cell engagers, in vivo protein therapeutics, and other advanced immunomodulatory modalities. NanoForge enables an end-to-end innovation chain spanning AI-based protein generation, in vivo delivery technologies, and next-generation immunotherapy development.
Strategic Significance
"This transaction represents an exciting development in the strategic alliance between METiS and Deerfield at a pivotal moment for AI-driven drug delivery innovation in China," said Chris Lai, Chairman and Chief Executive Officer of METiS TechBio (搜索). "The MTS-128 (搜索) program demonstrates NanoForge's ability to enable next-generation drug discovery and development. This is only the beginning."
Lai further emphasized the company's long-term vision: "Leveraging NanoForge as our core engine, we will continue to generate globally competitive therapeutic assets. As AI converges with drug delivery technologies, we aim to advance transformative therapies from concept to global development, bringing more accessible innovative treatments to patients worldwide."
The transaction marks what METiS TechBio (搜索) characterizes as a shift in AI-enabled drug delivery platforms from early technological validation toward global commercialization value realization. The company noted that the deal reflects validation from top-tier global capital and industry partners.
METiS TechBio (搜索), founded by a team of MIT-trained scientists with expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, successfully listed on the Hong Kong Stock Exchange on May 13, 2026, as the first publicly listed AI-powered drug delivery company. The company's platforms are designed to simulate, predict, and interpret nanoscale interactions to enable rational design, optimization, and validation of next-generation nanomaterials and their payloads across a range of diseases including cancer (搜索), metabolic and autoimmune disorders, and neurodegenerative conditions.